Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs
Authors
Keywords
-
Journal
DALTON TRANSACTIONS
Volume 40, Issue 31, Pages 7817
Publisher
Royal Society of Chemistry (RSC)
Online
2011-06-01
DOI
10.1039/c0dt01816c
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer
- (2010) Yun Fan et al. ACTA PHARMACOLOGICA SINICA
- Modulation of cell sensitivity to antitumor agents by targeting survival pathways
- (2010) Paola Perego et al. BIOCHEMICAL PHARMACOLOGY
- Ruthenium-based chemotherapeutics: are they ready for prime time?
- (2010) Emmanuel S. Antonarakis et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I/II and Pharmacokinetic Study of Intravenous Vinflunine in Combination With Cisplatin for the Treatment of Chemonaive Patients With Advanced Non–Small-Cell Lung Cancer
- (2010) Pierre-Jean Souquet et al. Clinical Lung Cancer
- A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer
- (2010) Hyeong Su Kim et al. LUNG CANCER
- New Platinum and Ruthenium Complexes - the Latest Class of Potential Chemotherapeutic Drugs - a Review of Recent Developments in the Field
- (2010) Amr Amin et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Targeting anoikis resistance in prostate cancer metastasis
- (2010) Shinichi Sakamoto et al. MOLECULAR ASPECTS OF MEDICINE
- EGFR Signaling and Drug Discovery
- (2010) Georg Lurje et al. ONCOLOGY
- Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells
- (2010) Justus Lieber et al. PEDIATRIC BLOOD & CANCER
- Forcing Cancer Cells to Commit Suicide
- (2009) Christel Vangestel et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- A Ruthenium-Containing Organometallic Compound Reduces Tumor Growth through Induction of the Endoplasmic Reticulum Stress Gene CHOP
- (2009) Xiangjun Meng et al. CANCER RESEARCH
- Targeting proteins with metal complexes
- (2009) Eric Meggers CHEMICAL COMMUNICATIONS
- Satraplatin for the therapy of castration-resistant prostate cancer
- (2009) Guru Sonpavde et al. Future Oncology
- Novel ways to sensitise gastrointestinal cancer to apoptosis
- (2009) H Schulze-Bergkamen et al. GUT
- Efficacy of taxane and platinum-based chemotherapy guided by extreme drug resistance assay in patients with epithelial ovarian cancer
- (2009) Won Deok Joo et al. Journal of Gynecologic Oncology
- In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model
- (2009) A. Bergamo et al. JOURNAL OF INORGANIC BIOCHEMISTRY
- Treatment of advanced non-small-cell lung cancer in the elderly
- (2009) Cesare Gridelli et al. LUNG CANCER
- Similar Biological Activities of Two Isostructural Ruthenium and Osmium Complexes
- (2008) Jasna Maksimoska et al. CHEMISTRY-A EUROPEAN JOURNAL
- Medicinal Organometallic Chemistry: Designing Metal Arene Complexes as Anticancer Agents
- (2008) Anna F. A. Peacock et al. Chemistry-An Asian Journal
- Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue
- (2008) H. Choy et al. CLINICAL CANCER RESEARCH
- The ruthenium(II)–arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53–JNK pathways
- (2008) Soumya Chatterjee et al. JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY
- Targeted manipulation of apoptosis in cancer treatment
- (2008) Justin A Call et al. LANCET ONCOLOGY
- Antitumour metal compounds: more than theme and variations
- (2007) Michael A. Jakupec et al. DALTON TRANSACTIONS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation